Showing 691-700 of 4005 results for "".
Octane Aesthetics Tech Forum: Artificial Intelligence’s Expanding Role in Aesthetic Medicine
https://reachmd.com/conferences/octane-atf-2026/octane-aesthetics-tech-forum-artificial-intelligences-expanding-role-in-aesthetic-medicine/54705/Jessica Wu, MD, Dermatologist, Author, and Founder & CEO of Residen, offers a grounded perspective on AI in aesthetics moving beyond hype to real-world application. She shares how AI is influencing clinical decision-making, where it is delivering measurable value in practice, and which emergingPractical Dermatology Jan/Feb 2026: Page-Turner Format
https://reachmd.com/issues/januaryfebruary-2026/practical-dermatology-janfeb-2026-page-turner-format/54455/Prevention and Control of Skin Cancer
https://reachmd.com/programs/grand-rounds-nation/prevention-and-control-skin-cancer/7472/Skin cancer is the most common form of cancer in the United States, affecting 5 million individuals each year. Melanoma, the third most common skin cancer, is the deadliest kind of skin cancer, resulting in approximately 9,000 deaths each year. Most cases of skin cancer are preventable, but despiteAllergic Contact Enteritis: Where Dermatology Meets Gastroenterology
https://reachmd.com/programs/primary-care-today/allergic-contact-enteritis-where-dermatology-gastroenterology-meet/8169/Dr. Michael Stierstorfer discusses intersections between dermatology and gastroenterology in the study of hypersensitivity reactions.The Autopsy that Changed American Sports: Dr. Bennett Omalu and the Story of CTE
https://reachmd.com/programs/clinicians-roundtable/the-autopsy-that-changed-american-sports-dr-bennett-omalu-and-the-story-of-cte/9979/Dr. Bennett Omalu shares the story of how he discovered evidence of CTE from autopsies of American football players.Pharmacologic Management of Behavioral Challenges and Psychiatric Comorbidities in People With Epilepsy
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/pharmacologic-management-of-behavioral-challenges-and-psychiatric-comorbidities-in-people-with-epilepsy/39969/Treatment of behavioral and psychiatric comorbidities in people with epilepsy requires careful consideration of underlying causes, symptom profile, antiseizure medications, and epilepsy type.PRP Scaffolds in Chronic Wound Care: A Move Toward Regenerative Solutions
https://reachmd.com/programs/clinicians-roundtable/prp-scaffolds-in-chronic-wound-care-a-move-toward-regenerative-solutions/36422/Zilucoplan: A Promising Potential Treatment for Myasthenia Gravis
https://reachmd.com/programs/neurofrontiers/zilucoplan-a-promising-potential-treatment-for-myasthenia-gravis/26392/Dive into a recent study that suggests zilucoplan could help treat MG symptoms.Potassium Channel Opener Promising for Seizure Freedom
https://reachmd.com/programs/practical-neurology/potassium-channel-opener-promising-for-seizure-freedom/49196/Investigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
https://reachmd.com/programs/neurofrontiers/investigating-inebilizumab-for-generalized-myasthenia-gravis-results-from-mint/35495/Recently published in The New England Journal of Medicine, the phase 3 Myasthenia Gravis Inebilizumab Trial (MINT) underscores the potential of inebilizumab as a therapeutic option for patients with generalized myasthenia gravis (gMG). This is based on the efficacy findings that inebilizumab signifi